Abstract
Objective To observe the improvement effect of femoston on symptoms and endocrine indexes of patients with climacteric syndrome. Methods A total of 120 patients with climacteric syndrome who were treated in Changzhi Maternal and Child Health Hospital from January 2014 to February 2018 were divided into two groups, 60 patients in the control group were treated with estradiol valerate tablets + progesterone capsules; 60 patients in the observation group were treated with femoston. Results After treatment, the improvement of endocrine index (estradiol, luteinizing hormone, follicle stimulating hormone) in the observation group were significantly better than those in the control group (P<0.05). After treatment, the Kupperman scores of the observation group were significantly lower than those of the control group (P<0.05); the total effective rate was 90% in the observation group and 76.67% in the control group, the difference was significant (P<0.05). Conclusions Femoston can effectively improve the endocrine index of patients with climacteric syndrome, alleviate the clinical symptoms of patients, improve the therapeutic effect. Key words: Menopausal syndrome; Femoston; Endocrine level
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
